Results 201 to 210 of about 1,086,070 (250)
Some of the next articles are maybe not open access.
Management of Multidrug-Resistant Tuberculosis
Seminars in Respiratory and Critical Care Medicine, 2013AbstractDrug-resistant strains of Mycobacterium tuberculosis pose a major threat to global tuberculosis control. Despite the availability of curative antituberculosis therapy for nearly half a century, inappropriate and inadequate treatment of tuberculosis, as well as unchecked transmission of M.
Charles L, Daley, Jose A, Caminero
openaire +3 more sources
Linezolid for multidrug-resistant tuberculosis
The Lancet Infectious Diseases, 2013In their Comment in The Lancet Infectious Diseases, Kwok-Chiu Chang and colleagues concluded that expansion of access to linezolid for complicated cases of drug-resistant tuberculosis risks the loss of a potentially useful drug and could promote the emergence and spread of drug-resistant tuberculosis in the community.
Helen, Cox +3 more
openaire +2 more sources
Multidrug-Resistant Tuberculosis Spondylitis
Acta Clinica Belgica, 2000We report a case of multidrug-resistant spinal tuberculosis complicated by epiduritis and paraspinal abscess in a 68-year-old black woman. Multidrug-resistant tuberculous spondylitis is still rare in Belgium. Two others cases were reported from 1992 to 1997.
Cherifi, Soraya +2 more
openaire +3 more sources
Treatment and Prevention of Multidrug-Resistant Tuberculosis [PDF]
Drugs, 1999 Multidrug-resistant tuberculosis (MDRTB), which is defined as combined resistance to isoniazid and rifampicin, is a 'man-made' disease that is caused by improper treatment, inadequate drug supplies or poor patient supervision. Patients with MDRTB face chronic disability and death, and represent an infectious hazard for the community.
Bastian, I., Colebunders, R.
openaire +3 more sources
Confronting Multidrug-Resistant Tuberculosis
New England Journal of Medicine, 2012Microbial resistance to antituberculosis drugs has existed since the dawn of the antibiotic era.1 Multidrug-resistant (MDR) tuberculosis, defined by resistance to isoniazid and rifampin, requires treatment for up to 2 years with expensive second-line drugs that have poor side-effect profiles; success rates rarely exceed 65 to 75%.
Richard E, Chaisson, Eric L, Nuermberger
openaire +2 more sources
Multidrug-resistant tuberculosis
Infectious Disease Clinics of North America, 2002Multidrug-resistant TB is a growing public health problem. Although control of the multidrug-resistant TB epidemic has been achieved in New York City, strains of multidrug-resistant TB are found in nearly every state. Much of the world faces a growing problem with no immediate solution.
openaire +2 more sources
Multidrug‐Resistant Tuberculosis
Annals of the New York Academy of Sciences, 2001Abstract: The costs of multidrug‐resistant tuberculosis (MDR TB) reach far beyond the cost of the clinical treatment of the patient. The first impact of the discovery of MDR TB in a population is the need to recognize that all TB patients have the potential of being MDR.
openaire +2 more sources
Multidrug resistance in Mycobacterium tuberculosis
International Journal of Antimicrobial Agents, 1997All but one of the four major mechanisms of resistance to antimicrobial agents-inactivation of the drug, altered cell wall permeability or drug efflux, drug titration due to target overproduction, and alteration of the target by mutation-appear to be employed by Mycobacterium tuberculosis in its resistance to components of short course chemotherapy ...
Heym, B, Cole, S T
openaire +3 more sources
Treatment of Multidrug-Resistant Tuberculosis
New England Journal of Medicine, 1993The frequency of infections with M. tuberculosis resistant to antituberculous drugs is increasing in the United States and globally. This increase is a major threat to tuberculosis treatment and control programs. To prevent this situation from worsening, initial treatment programs that entail directly observed therapy supported by effective inducements
Alastair J.J. Wood, Michael D. Iseman
openaire +2 more sources
▼Bedaquiline for multidrug-resistant tuberculosis
Drug and Therapeutics Bulletin, 2014Resistance to drugs used to treat tuberculosis (TB) is a major public health problem that threatens progress made in TB management and control worldwide.1 It may result from improper use of antibiotics, including prescription of non-standard treatment regimens and poor adherence to drug therapy.
openaire +2 more sources